CMND has come out firing this morning while make a smoking hot green chart push.


(CMND) Makes An Impressive Early Green Push, Currently Up Approximately 12% (Read Immediately)

November 25th

Greetings Readers,

CMND has come out firing this morning while making a smoking hot green chart push.

Currently up approximately 12%, CMND has already nailed an early high of $5.61.

Could more be on the way?

Remember, this is a low float idea with Yahoo Finance reporting fewer than 2Mn shares in its float. Volatility could have the potential to show up at a moment's notice.

There isn't a ton of technical info as CMND only recently uplisted to the Nasdaq so exposure to this under the radar company should continue to grow as more people learn of what they've been up to.

And if their November news is any indicator, CMND will need a spot towards the top of your watch-list moving forward.

Take a second to get CMND on your radar before it's too late and read my initial report below.


In case you missed it, my Tuesday alert went bonkers within 36 hours.

Running approximately 43% from Tuesday's open of $1.27 to a $1.82 high Wednesday, this latest Nasdaq runner exploded ahead of Turkey Day.

While you guys were tracking that profile, I turned my attention to a new Nasdaq idea displaying a ton of breakout potential.

And when I saw it had a spicy low float under 2Mn shares, had a recent Nasdaq uplisting, and dropped strong November news regarding progression towards a First In Human (FIH) clinical trial for a novel drug candidate, I knew it needed top spot on your watch-list Friday.

Drop everything and get this little-known Nasdaq idea on your radar now:

*Clearmind Medicine Inc. (CMND)*

Clearmind is a psych-e-delic pharmaceutical biotech company focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

And based on these 4 potential catalysts, CMND needs immediate attention. Check them out:

No. 1 - A Tiny Float Could Provide Access To Extreme Volatility

No. 2 - Clearmind Continues Its Progress Toward FIH Clinical Trial For CMND-100

No. 3 - Nasdaq Uplisting Creates Incredible Exposure Opp.

No. 4 - Company Files Provisional Patent Application Related To Metabolic Syndromes (Including Obesity)

But more on those in a second...

The Problem: Alcohol Use Disorder.

Clearmind’s flagship treatments are focused on Alcohol Use Disorder (AUD), which is incredibly common. It varies from mild to excessive, and describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences.

  • Alcohol consumption is the 3rd leading preventable cause of death in the US.
  • The yearly cost of excessive alcohol use in the US reached $249Bn in 2010.
  • Alcohol consumption contributes to 3 million deaths each year globally... In addition to disabilities and poor health of millions of people. - World Health Organization


The Solution: MEAI (5-Methoxy-2-aminoindane)

5-Methoxy-2-aminoindane (MEAI) is a psychoactive molecule, exerting a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages. It shows a good safety profile in pre-clinical studies, with potential to change the lives of millions who struggle to drink in moderation.

Breaking the Cycle

We believe that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behaviour.”


Anecdotal reports and pre-clinical in-vivo results indicate the self-limiting property of MEAI—unlike traditional treatments.

Expansive Potential

The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.


Successful Pre-clinical Results In MEAI Treatment For Alcohol Consumption

Pre-clinical trial demonstrated a high safety profile in addition to a significant suppressive effect on alcohol consumption.

  • Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks
  • The groups were then given a daily dose of MEAI, with intermittent access to alcohol and water
  • After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving MEAI
  • The untreated control group showed no significant reduction in alcohol consumption
  • No SAEs or treatment-related histological changes were observed amongst all MEAI treatment groups compared to control naive and vehicle animals in all the examined organs

Low Competitive Intensity

Only 3 other psych-e-delic companies are working on alcohol abuse problems:


The Company's Competitive Advantage

Most companies in the psych-e-delics field target depression and anxiety.

  • Clearmind focuses on binge behaviors and addictions: A huge untapped market

Most companies develop classic psych-e-delics for which intellectual property is hard to file and approve.

  • Clearmind is the sole developer of MEAI and has a robust portfolio of protected intellectual property

Most psych-e-delic treatments are designed to be adjuncts to psychotherapy.

  • MEAI is designed to be self administered, due to its high safety potential, and not in conjunction to psychotherapy


Expected Timeline


Grab Sources And More From The CMND Company Presentation.


And as I mentioned above, CMND has several potential catalysts that could provide a breakout spark near term. Here they are:

No. 1 CMND Potential Catalyst - A Tiny Float Could Provide Access To Extreme Volatility

According to the Yahoo Finance website, CMND has a tiny float.

The website reports this profile to have approximately 1.29Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.


No. 2 CMND Potential Catalyst - Clearmind Continues Its Progress Toward FIH Clinical Trial For CMND-100

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psych-e-delic-derived drug candidate, the MEAI- based molecule- CMND-100.

The produced batches will be used in the Company's upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Following MEAI's synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company's pre- clinical studies designed to evaluate the safety of its innovative compound.

"Clearmind continues its progress toward FIH clinical trial," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. "This milestone joins other achievements we've made in a relatively short period. Non-clinical data generated to date demonstrate that our MEAI- based treatment has the potential to treat a broad range of addictions and binge behaviors such as AUD."

"Like other addictions, AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use," she added. "Alcohol abuse is the third most-common preventable cause of death in the United States, where almost 6% struggle with this condition."

The Company previously announced that it completed a highly constructive Pre-Investigational New Drug Application ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the development of CMND-100.

Read the full article here.


No. 3 CMND Potential Catalyst - Nasdaq Uplisting Creates Incredible Exposure Opp.

Clearmind Medicine Announces Closing of $7.5Mn Public Offering and Uplisting to the Nasdaq Capital Market

VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), ..., today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of $6.50 per share (CAD$8.65), for aggregate gross proceeds of $7.5Mn, prior to deducting underwriting discounts and offering expenses. The closing occurs following a 1-for-30 reverse st-ock split, which was effective at 5:30 p.m. on September 30, 2022.


Read the full article here.

Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)

NEW YORK, NY / ACCESSWIRE / November 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ:CMND).

Read the full article here.


No. 4 CMND Potential Catalyst - Company Files Provisional Patent Application Related To Metabolic Syndromes (Including Obesity)

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd.

VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), ..., today announced it has filed a provisional patent application related to metabolic syndromes including obesity.

The patent application is another result of the company’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with the Hebrew University of Jerusalem.

The patent application is the third application resulting from the collaboration with SciSparc, referring to the proprietary combination of Clearmind's MEAI, a novel proprietary psych-e-delic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™, which is used for treating obesity and its related metabolic disorders.

"Food addiction and obesity are an epidemic raging in the United States and around the world, yet there are few safe and effective anti-obesity treatments on the market," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer.

"In pre-clinical studies MEAI has shown great potential in its ability to treat different addictions. Certain metabolic syndromes Can be associated to addictive behaviors, and we believe combining MEAI with SciSparc's CannAmide™ may create a valuable tool for treating these conditions."

The study was conducted as part of Clearmind’s research and development projects with the Hebrew University’s Obesity and Metabolism Laboratory, which is led by Joseph Tam, D.M.D., Ph.D., Associate Professor of Pharmacology at the University’s Institute for Drug Research.

This new patent application continues Clearmind’s strategy since inception to enhance its IP portfolio to create state-of-the-art psych-e-delic drug candidates, to better serve patients in need,” said Dr. Zuloff-Shani.

Read the full article here.


CMND Recap - This Nasdaq's Top 4 Potential Breakout Catalysts

No. 1 - A Tiny Float Could Provide Access To Extreme Volatility

No. 2 - Clearmind Continues Its Progress Toward FIH Clinical Trial For CMND-100

No. 3 - Nasdaq Uplisting Creates Incredible Exposure Opp.

No. 4 - Company Files Provisional Patent Application Related To Metabolic Syndromes (Including Obesity)


Coverage is officially initiated on CMND. When time permits, do this:


Get CMND on your radar now.


Kai Parker


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 11/23/22 and ending on 11/25/22 to publicly disseminate information about (CMND) via Website, Email and SMS. SWN Media LLC was paid ten thousand USD via bank wire transfer. We own zero shares of (CMND).